
Stereotaxis STXS
$ 1.93
-1.53%
Annual report 2025
added 03-12-2026
Stereotaxis Total Assets 2011-2026 | STXS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Stereotaxis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.3 M | 46.7 M | 41.9 M | 53.4 M | 61 M | 55.5 M | 43.6 M | 18.5 M | 10.7 M | 21 M | 19.2 M | 23.9 M | 31.1 M | 32.2 M | 39.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61 M | 10.7 M | 36.7 M |
Quarterly Total Assets Stereotaxis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.6 M | 41.2 M | 45.7 M | 50.9 M | 36 M | 39.5 M | 44.5 M | 48.3 M | 50.7 M | 53.4 M | 56.1 M | 56.7 M | 57.4 M | 61 M | 61.9 M | 57.3 M | 58.8 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 21 M | 21 M | 21 M | 21 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.9 M | 10.7 M | 35.9 M |
Total Assets of other stocks in the Medical instruments industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
261 K | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
825 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
10.9 M | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
31.6 B | $ 75.8 | -0.08 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
20.1 M | $ 10.99 | 1.48 % | $ 26.7 M | ||
|
The Cooper Companies
COO
|
12.4 B | $ 64.42 | -0.82 % | $ 12.8 B | ||
|
Antares Pharma, Inc.
ATRS
|
213 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
2.07 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
192 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
4.67 B | - | -0.05 % | $ 10.3 B | ||
|
iRhythm Technologies
IRTC
|
1.02 B | $ 122.35 | 0.73 % | $ 3.92 B | ||
|
Varian Medical Systems, Inc.
VAR
|
4.46 B | - | -0.02 % | $ 16.3 B | ||
|
Repro Med Systems
KRMD
|
28.2 M | $ 3.96 | -0.75 % | $ 183 M | ||
|
Haemonetics Corporation
HAE
|
2.45 B | $ 59.93 | 0.52 % | $ 3.02 B | ||
|
electroCore
ECOR
|
18.7 M | $ 6.18 | -0.08 % | $ 52.4 K | ||
|
ICU Medical
ICUI
|
4.05 B | $ 124.82 | 0.22 % | $ 3.08 B | ||
|
Envista Holdings Corporation
NVST
|
5.68 B | $ 26.8 | -0.89 % | $ 4.5 B | ||
|
Microbot Medical
MBOT
|
81.5 M | $ 2.2 | 0.92 % | $ 101 M | ||
|
Isoray
ISR
|
267 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
20.5 B | $ 482.22 | 0.71 % | $ 172 B | ||
|
Glaukos Corporation
GKOS
|
940 M | $ 121.48 | 0.5 % | $ 5.88 B | ||
|
Masimo Corporation
MASI
|
2.63 B | $ 178.63 | -0.04 % | $ 9.52 B | ||
|
Milestone Scientific
MLSS
|
7.81 M | $ 0.32 | -1.27 % | $ 26.3 M | ||
|
InfuSystem Holdings
INFU
|
99.4 M | $ 10.34 | 0.68 % | $ 214 M | ||
|
Merit Medical Systems
MMSI
|
2.69 B | $ 68.58 | -0.04 % | $ 4.06 B | ||
|
Pulse Biosciences
PLSE
|
94.5 M | $ 23.02 | -5.07 % | $ 1.55 B | ||
|
Retractable Technologies
RVP
|
143 M | $ 0.65 | 0.2 % | $ 19.5 M | ||
|
Pro-Dex
PDEX
|
61.2 M | $ 52.1 | 2.24 % | $ 171 M | ||
|
LeMaitre Vascular
LMAT
|
616 M | $ 113.45 | 0.49 % | $ 2.57 B | ||
|
Predictive Oncology
POAI
|
52.9 M | - | - | $ 31.1 M | ||
|
STAAR Surgical Company
STAA
|
452 M | $ 25.67 | 3.34 % | $ 1.27 B | ||
|
STERIS plc
STE
|
10.1 B | $ 221.8 | -0.77 % | $ 21.9 B | ||
|
BioLife Solutions
BLFS
|
399 M | $ 21.38 | -1.57 % | $ 985 M | ||
|
Baxter International
BAX
|
20.1 B | $ 18.16 | -1.39 % | $ 9.32 B | ||
|
ResMed
RMD
|
5.1 B | $ 219.85 | 0.15 % | $ 32.1 B | ||
|
Teleflex Incorporated
TFX
|
6.95 B | $ 136.56 | -0.07 % | $ 6.09 B | ||
|
AtriCure
ATRC
|
654 M | $ 29.28 | 3.79 % | $ 1.4 B | ||
|
Harvard Bioscience
HBIO
|
80.1 M | $ 6.86 | 1.18 % | $ 305 M | ||
|
Utah Medical Products
UTMD
|
123 M | $ 67.17 | -1.03 % | $ 218 M | ||
|
NeuroMetrix
NURO
|
15.3 M | - | 5.05 % | $ 9.02 M | ||
|
West Pharmaceutical Services
WST
|
4.27 B | $ 306.16 | -1.14 % | $ 22.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
5.43 B | $ 11.91 | 0.08 % | $ 2.37 B | ||
|
AngioDynamics
ANGO
|
280 M | $ 11.1 | -0.89 % | $ 453 M | ||
|
Becton, Dickinson and Company
BDX
|
55.3 B | $ 152.14 | -1.74 % | $ 43.8 B | ||
|
Nephros
NEPH
|
11.9 M | $ 2.87 | 1.06 % | $ 29.8 M | ||
|
OraSure Technologies
OSUR
|
403 M | $ 3.0 | -1.64 % | $ 220 M | ||
|
Repligen Corporation
RGEN
|
2.83 B | $ 117.6 | 3.1 % | $ 6.55 M |